Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Cardiovascular Systems, Inc.

CSIINASDAQ
Healthcare
Medical - Devices
$20.00
$0.03(0.15%)
U.S. Market opens in 11h 20m

Cardiovascular Systems, Inc. Fundamental Analysis

Cardiovascular Systems, Inc. (CSII) shows weak financial fundamentals with a PE ratio of -21.24, profit margin of -15.63%, and ROE of -14.19%. The company generates $0.3B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position20.37%
PEG Ratio-0.21
Current Ratio6.05

Areas of Concern

ROE-14.19%
Operating Margin-15.16%
We analyze CSII's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 2.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
2.7/100

We analyze CSII's fundamental strength across five key dimensions:

Efficiency Score

Weak

CSII struggles to generate sufficient returns from assets.

ROA > 10%
-11.45%

Valuation Score

Excellent

CSII trades at attractive valuation levels.

PE < 25
-21.24
PEG Ratio < 2
-0.21

Growth Score

Weak

CSII faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

CSII maintains a strong and stable balance sheet.

Debt/Equity < 1
0.08
Current Ratio > 1
6.05

Profitability Score

Weak

CSII struggles to sustain strong margins.

ROE > 15%
-1419.30%
Net Margin ≥ 15%
-15.63%
Positive Free Cash Flow
No

Key Financial Metrics

Is CSII Expensive or Cheap?

P/E Ratio

CSII trades at -21.24 times earnings. This suggests potential undervaluation.

-21.24

PEG Ratio

When adjusting for growth, CSII's PEG of -0.21 indicates potential undervaluation.

-0.21

Price to Book

The market values Cardiovascular Systems, Inc. at 3.14 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.14

EV/EBITDA

Enterprise value stands at -26.45 times EBITDA. This is generally considered low.

-26.45

How Well Does CSII Make Money?

Net Profit Margin

For every $100 in sales, Cardiovascular Systems, Inc. keeps $-15.63 as profit after all expenses.

-15.63%

Operating Margin

Core operations generate -15.16 in profit for every $100 in revenue, before interest and taxes.

-15.16%

ROE

Management delivers $-14.19 in profit for every $100 of shareholder equity.

-14.19%

ROA

Cardiovascular Systems, Inc. generates $-11.45 in profit for every $100 in assets, demonstrating efficient asset deployment.

-11.45%

Following the Money - Real Cash Generation

Operating Cash Flow

Cardiovascular Systems, Inc. generates limited operating cash flow of $-26.11M, signaling weaker underlying cash strength.

$-26.11M

Free Cash Flow

Cardiovascular Systems, Inc. generates weak or negative free cash flow of $-30.65M, restricting financial flexibility.

$-30.65M

FCF Per Share

Each share generates $-0.73 in free cash annually.

$-0.73

FCF Yield

CSII converts -3.38% of its market value into free cash.

-3.38%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-21.24

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.21

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.14

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.57

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

6.05

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.14

vs 25 benchmark

ROA

Return on assets percentage

-0.11

vs 25 benchmark

ROCE

Return on capital employed

-0.13

vs 25 benchmark

How CSII Stacks Against Its Sector Peers

MetricCSII ValueSector AveragePerformance
P/E Ratio-21.2429.28 Better (Cheaper)
ROE-14.19%820.00% Weak
Net Margin-15.63%-19731.00% (disorted) Weak
Debt/Equity0.080.26 Strong (Low Leverage)
Current Ratio6.054.69 Strong Liquidity
ROA-11.45%-17993.00% (disorted) Weak

CSII outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Cardiovascular Systems, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ